Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
25 avr. 2024 07h00 HE
|
Purple Biotech Ltd.
Interim data suggests reduced risk of progression or death in the CM24/nivolumab plus standard of care Nal-IRI/5FU/LV arm of the study REHOVOT, Israel, April 25, 2024 (GLOBE NEWSWIRE) --...
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
28 mars 2024 07h00 HE
|
Purple Biotech Ltd.
NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in...
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
14 mars 2024 07h30 HE
|
Purple Biotech Ltd.
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which...
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
05 mars 2024 07h55 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
27 févr. 2024 07h00 HE
|
Purple Biotech Ltd.
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024...
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
13 févr. 2024 07h00 HE
|
Purple Biotech Ltd.
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE:...
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
01 févr. 2024 07h30 HE
|
Purple Biotech Ltd.
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
20 déc. 2023 08h05 HE
|
Purple Biotech Ltd.
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company’s Chief Business...
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
14 déc. 2023 06h50 HE
|
Purple Biotech Ltd.
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple...
Purple Biotech Reports Third Quarter 2023 Financial Results
21 nov. 2023 06h50 HE
|
Purple Biotech Ltd.
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1/2 Dose Escalation Study Patients’ Enrollment in the Phase 2 Randomized CM24 Pancreatic Cancer Trial Ahead of Timelines Cash...